This page shows the latest Aimmune news and features for those working in and with pharma, biotech and healthcare.
Approval in the EU comes nine months after US authorisation. Aimmune Therapeutics’ Palforzia has received approval from the European Commission (EC) for the treatment of a peanut allergy. ... Aimmune’s potential rival, DBV Technologies, has not had
Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug. Nestlé has announced plans to acquire allergy specialist Aimmune Therapeutics in a deal worth $2.6bn, six months after ... Aimmune’s launch of Palforzia has been hampered by
Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... Every month of delay gives Aimmune more time to extend its
Aimmune has also filed for approval in Europe, with a verdict due later this year. ... Analysts at GlobalData have suggested the market for peanut allergy products in eight major world markets could be worth $4.5bn in 2027, with Aimmune claiming a
Step closer to becoming first approved treatment. Aimmune’s AR101 has moved a step closer to becoming the first approved peanut allergy treatment in the US after an FDA advisory committee ... Aimmune has also been filed for approval in Europe, with a
four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... Aimmune is expecting an approval decision on AR101 by January 2020, and the FDA has planned an advisory committee
More from news
Approximately 9 fully matching, plus 2 partially matching documents found.
Aimmune Therapeutics prepared for commercialisation by using two PRO scales to show the effect of its peanut allergy drug on people’s emotions and social lives.
Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy. ... However, Aimmune reported in February 2019 that the FDA had initially determined that the drug, as an allergenic extract, was exempt from the
Now a US biotech company, Aimmune, looks set to bring the first treatment to market by the end of this year. ... Aimmune Therapeutics submitted the drug to the FDA on 21 December.
licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...